CHICAGO, Dec 14 (Reuters) - Women who took AstraZeneca Plc's breast cancer drug Arimidex fared better than those who took the pill tamoxifen even four years after they stopped taking it, researchers ...
June 12, 2006 (Atlanta) — Women with breast cancer who are treated with the aromatase inhibitor anastrozole (Arimidex, AstraZeneca) for 5 years can lose 6% to 7% in bone-mineral density (BMD), enough ...
A total of 1,021 women were enrolled onto the QoL subprotocol. All had completed primary treatment (surgery ± radiotherapy ± chemotherapy) and were to receive 5 years of adjuvant treatment with ...
A new study published in The Lancet Oncology discusses the efficacy of anastrozole, a molecule used to prevent breast cancer in postmenopausal women with a high risk of breast cancer. Study: Effect of ...
Anastrozole, an aromatase inhibitor, is widely prescribed for oestrogen receptor-positive breast cancer. Although effective, it has been linked to autoimmune hepatitis (AIH), a rare but serious ...
Patients with chemotherapy-naïve, HER2-low hormone receptor-positive metastatic breast cancer experienced antitumor activity via combination therapy with Arimidex or Faslodex plus Enhertu, according ...
Double-Blind, Randomized Trial Comparing the Efficacy and Tolerability of Fulvestrant Versus Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing on Prior Endocrine Therapy: ...
The news that the U.K. has approved a preventive drug for post-menopausal women at risk of developing breast cancer wasn’t a shock to breast medical oncologist Abenaa Brewster. But the fact that a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback